Cyclacel Pharmaceuticals, Inc. to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting

BERKELEY HEIGHTS, N.J., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of advanced myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at two poster presentations during the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA, on Saturday, December 5, 2009.
MORE ON THIS TOPIC